Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Earnings Data
Report Date
Mar 11, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.31Last Year’s EPS
-0.58Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.Company Guidance
Extraordinary Overall Survival in Pancreatic Cancer
In September, Immuneering Corporation announced 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine nab-paclitaxel, compared to approximately 47% with the standard of care.
Successful Financing and Extended Cash Runway
The company strengthened its balance sheet with $225 million in cumulative financing, including a $25 million strategic investment from Sanofi, extending the cash runway into 2029.
Positive Case Studies in Pancreatic Cancer Treatment
Noteworthy case studies demonstrated impressive responses, including complete response and conversion to surgical candidates, highlighting atebimetinib's potential in combination with FOLFIRINOX.
Patent Protection and New Collaborations
Immuneering was granted a U.S. Composition of Matter patent for atebimetinib, providing exclusivity into 2042, and announced collaborations with Eli Lilly and Regeneron for lung cancer trials.
IMRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $6.62 | $6.45 | -2.57% |
Aug 13, 2025 | $3.22 | $3.04 | -5.59% |
May 05, 2025 | $1.25 | $1.19 | -4.80% |
Mar 20, 2025 | $1.65 | $1.80 | +9.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immuneering (IMRX) report earnings?
Immuneering (IMRX) is schdueled to report earning on Mar 11, 2026, Before Open (Confirmed).
What is Immuneering (IMRX) earnings time?
Immuneering (IMRX) earnings time is at Mar 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMRX EPS forecast?
IMRX EPS forecast for the fiscal quarter 2025 (Q4) is -0.31.